Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK.
Mult Scler. 2024 Aug;30(9):1221-1226. doi: 10.1177/13524585241258691. Epub 2024 Jun 14.
Conflicting data exist around oral contraceptive exposure and subsequent multiple sclerosis (MS).
To use routinely collected primary healthcare data to explore the potential association between oral contraceptive exposure and subsequent MS in females at population level.
We performed a nested case-control study using electronic primary care data, with complete electronic ascertainment from 1990. Logistic regression was used to evaluate associations between contraceptive exposure and MS, without and with adjusting for age, ethnicity and deprivation.
A total of 4455 females were included: 891 cases and 3564 controls. No association was seen between oral contraceptive exposure and subsequent MS, or between any contraceptive, combined oral contraceptive pill (COCP) or progesterone-only pill (POP) use 0-2, 2-5 or >5 years prior to MS. Conclusions: In the largest population-based study to date, we find no evidence of an association between oral contraceptive exposure and subsequent MS diagnosis.
关于口服避孕药暴露与随后发生多发性硬化症（MS）之间的关系，存在相互矛盾的数据。
利用常规收集的初级保健数据，在人群水平上探索口服避孕药暴露与女性随后发生 MS 之间的潜在关联。
我们使用电子初级保健数据进行了一项嵌套病例对照研究，从 1990 年开始进行了完整的电子确定。使用逻辑回归评估了避孕方法暴露与 MS 之间的关联，未调整和调整了年龄、种族和贫困因素。
共纳入 4455 名女性：891 例病例和 3564 例对照。口服避孕药暴露与随后发生的 MS 之间或任何避孕方法、联合口服避孕药（COCP）或孕激素仅避孕药（POP）使用 0-2、2-5 或 >5 年前与 MS 之间均未见关联。
在迄今为止最大的基于人群的研究中，我们没有发现口服避孕药暴露与随后发生 MS 诊断之间存在关联的证据。
Zotero 插件